CEO Thomas Polen was paid $17,129,140 in fiscal year 2025, ↓ down 1.1% from fiscal year 2024, the 20th percentile of its disclosed peer group (SEC filing 0001628280-25-057846 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$17,129,140 ↓ Thomas Polen total, FY2025 | 20th CEO pay percentile vs peers | 374:1 CEO-to-median pay ratio | 91.41% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
BDX's next annual pay disclosure, estimated December 17, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Polen | $1,395,463 | $0 | $9,991,854 | $3,311,861 | $1,852,010 | $236,700 | $341,251 | $17,129,140 |
| Chairman, Chief Executive Officer and President | ||||||||
| Christopher DelOrefice | 837,500 | 0 | 3,140,481 | 1,040,916 | 722,500 | 0 | 135,767 | 5,877,164 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Michael Feld | 775,000 | 0 | 1,641,596 | 544,118 | 533,588 | 0 | 602,054 | 4,096,356 |
| Executive Vice President, Chief Revenue Officer and President, Life Sciences Segment | ||||||||
| Michael Garrison | 768,750 | 0 | 1,641,596 | 544,118 | 533,588 | 102,800 | 58,188 | 3,649,040 |
| Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | ||||||||
| Richard Byrd | 756,250 | 0 | 1,427,531 | 473,139 | 592,875 | 91,833 | 57,429 | 3,399,056 |
| Executive Vice President and President, Interventional Segment | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Polen | $17,129,140 | $17,314,606 | $17,309,938 | ↓ −185,466 |
| Christopher DelOrefice | 5,877,164 | 5,628,654 | 5,206,390 | ↑ +248,510 |
| Michael Feld | 4,096,356 | — | — | — |
| Michael Garrison | 3,649,040 | 3,622,082 | 3,654,368 | ↑ +26,958 |
| Richard Byrd | 3,399,056 | 3,268,663 | — | ↑ +130,393 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read BECTON DICKINSON & CO's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BDX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the BECTON DICKINSON & CO Peer Teardown Report
$17,129,140 Thomas Polen total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of September 29, 2026 · Source: 0001628280-25-057846 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for BDX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order BDX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name BDX as a peer is temporarily unavailable — recheck shortly.
Get the BECTON DICKINSON & CO Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Christopher DelOrefice | CFO | $5,877,164 |
| Richard Byrd | EVP | $3,399,056 |
| Michael Feld | President | $4,096,356 |
| Michael Garrison | EVP | $3,649,040 |
| Thomas Polen | CEO | $17,129,140 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Bertram L. Scott | Lead Independent Director | $375,172 |
| Carrie L. Byington | Independent Director | $345,172 |
| Catherine M. Burzik | Independent Director | $360,172 |
| Christopher Jones | Independent Director | $365,172 |
| Claire M. Fraser | Independent Director | $344,672 |
| Gregory J. Hayes | Independent Director | $223,454 |
| Jacqueline Wright | Independent Director | — |
| Jeffrey W. Henderson | Independent Director | $360,172 |
| Joanne Waldstreicher | Independent Director | $336,172 |
| R. Andrew Eckert | Independent Director | $365,172 |
| Robert L. Huffines | Independent Director | — |
| Timothy M. Ring | Independent Director | $335,172 |
| William M. Brown | Independent Director | $335,172 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2025-12-26 | D | 74 | $196 | $14,510 | Common | Form 4 ↗ |
| David Shan | EVP and Chief ISC Officer | 2026-01-03 | D | 44 | 0 | 0 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 2,454 | 209 | 512,886 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 1,010 | 207 | 208,605 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 3,054 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | A | 3,054 | 168 | 512,797 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 600 | 209 | 125,400 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-01-21 | D | 84 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2026-01-26 | D | 75 | 203 | 15,205 | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| R. Andrew Eckert | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Hayes | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Henderson | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jacqueline Wright | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| William M. Brown | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-04 | — | 30 | — | ~6,057 | 1 insider, 1 accrual row | ||
| Christopher Jones | Director | 2026-02-04 | A | 272 | 202 | 54,920 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-02-04 | A | 100 | 202 | 20,191 | Derivative, Class A Common | Form 4 ↗ |
| BECTON DICKINSON & CO | Greater-than-10% holder | 2026-02-09 | D | 284,771,350 | — | — | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-02-18 | D | 953 | 183 | 174,027 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-02-26 | D | 75 | 182 | 13,638 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Vitor Roque | Interim CFO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Lanesha Minnix | EVP and General Counsel | 2026-03-16 | A | 7,492 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-03-26 | D | 75 | 157 | 11,762 | Common | Form 4 ↗ |
| Shana Carol Neal | EVP and Chief People Officer | 2026-04-06 | D | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-04-27 | D | 74 | 152 | 11,244 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-05-07 | A | 1,721 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-05-08 | A | 105 | 149 | 15,649 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-05-08 | A | 210 | 149 | 31,298 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-05-26 | D | 75 | 147 | 11,051 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 20,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Menziuso | EVP and President, BDI | 2026-06-01 | A | 14,258 | 0 | 0 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 2,764 | 146 | 404,511 | Common, open-market sale | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 17,445 | 146 | 2,549,587 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | A | 20,209 | 126 | 2,549,567 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-10 | D | 1,100 | 151 | 166,628 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-24 | D | 1,100 | 146 | 160,226 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-06-26 | D | 75 | 153 | 11,460 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | A | 14,342 | 0 | 0 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-02 | D | 1,935 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-07-27 | D | 75 | 157 | 11,785 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-08-06 | A | 94 | 166 | 15,568 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-08-06 | A | 189 | 166 | 31,302 | Derivative, Class A Common | Form 4 ↗ |
| Roland Goette | EVP and President, EMEA | 2026-08-11 | D | 2,438 | 181 | 440,888 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 4,152 | 185 | 768,120 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 39,126 | 185 | 7,238,310 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | A | 43,278 | 167 | 7,238,246 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 43,278 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-08-20 | D | 1,049 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-08-26 | D | 165 | 188 | 31,101 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-09-02 | D | 190 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-09-28 | D | 76 | 184 | 13,961 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2025-12-26 | D | 74 | $196 | $14,510 | Common | Form 4 ↗ |
| David Shan | EVP and Chief ISC Officer | 2026-01-03 | D | 44 | 0 | 0 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 2,454 | 209 | 512,886 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 1,010 | 207 | 208,605 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 3,054 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | A | 3,054 | 168 | 512,797 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 600 | 209 | 125,400 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-01-21 | D | 84 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2026-01-26 | D | 75 | 203 | 15,205 | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| R. Andrew Eckert | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Hayes | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey W. Henderson | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jacqueline Wright | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| William M. Brown | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-02-04 | A | 30 | 202 | 6,057 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-02-04 | A | 272 | 202 | 54,920 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-02-04 | A | 100 | 202 | 20,191 | Derivative, Class A Common | Form 4 ↗ |
| BECTON DICKINSON & CO | Greater-than-10% holder | 2026-02-09 | D | 284,771,350 | — | — | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-02-18 | D | 953 | 183 | 174,027 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-02-26 | D | 75 | 182 | 13,638 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Vitor Roque | Interim CFO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Lanesha Minnix | EVP and General Counsel | 2026-03-16 | A | 7,492 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-03-26 | D | 75 | 157 | 11,762 | Common | Form 4 ↗ |
| Shana Carol Neal | EVP and Chief People Officer | 2026-04-06 | D | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-04-27 | D | 74 | 152 | 11,244 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-05-07 | A | 1,721 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-05-08 | A | 105 | 149 | 15,649 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-05-08 | A | 210 | 149 | 31,298 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-05-26 | D | 75 | 147 | 11,051 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 20,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Menziuso | EVP and President, BDI | 2026-06-01 | A | 14,258 | 0 | 0 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 2,764 | 146 | 404,511 | Common, open-market sale | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 17,445 | 146 | 2,549,587 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | A | 20,209 | 126 | 2,549,567 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-10 | D | 1,100 | 151 | 166,628 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-24 | D | 1,100 | 146 | 160,226 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-06-26 | D | 75 | 153 | 11,460 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | A | 14,342 | 0 | 0 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-02 | D | 1,935 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-07-27 | D | 75 | 157 | 11,785 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-08-06 | A | 94 | 166 | 15,568 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-08-06 | A | 189 | 166 | 31,302 | Derivative, Class A Common | Form 4 ↗ |
| Roland Goette | EVP and President, EMEA | 2026-08-11 | D | 2,438 | 181 | 440,888 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 4,152 | 185 | 768,120 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 39,126 | 185 | 7,238,310 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | A | 43,278 | 167 | 7,238,246 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-08-13 | D | 43,278 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-08-20 | D | 1,049 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-08-26 | D | 165 | 188 | 31,101 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-09-02 | D | 190 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-09-28 | D | 76 | 184 | 13,961 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Feld | PSU | 2024-11-26 | 2,543 | 5,085 | — | 10,170 | $1,090,122 |
| Michael Garrison | PSU | 2024-11-26 | 2,543 | 5,085 | — | 10,170 | 1,090,122 |
| Richard Byrd | RSU | 2024-11-26 | — | — | 8,699 | — | 473,139 |
| Christopher DelOrefice | RSU | 2024-11-26 | — | — | 19,138 | — | 1,040,916 |
| Thomas Polen | PSU | 2024-11-26 | 15,476 | 30,951 | — | 61,902 | 6,635,275 |
| Michael Feld | RSU | 2024-11-26 | — | — | 2,553 | — | 551,474 |
| Richard Byrd | RSU | 2024-11-26 | — | — | 2,220 | — | 479,542 |
| Michael Garrison | RSU | 2024-11-26 | — | — | 2,553 | — | 551,474 |
| Thomas Polen | RSU | 2024-11-26 | — | — | 15,539 | — | 3,356,579 |
| Christopher DelOrefice | RSU | 2024-11-26 | — | — | 4,884 | — | 1,054,993 |
| Christopher DelOrefice | PSU | 2024-11-26 | 4,864 | 9,728 | — | 19,456 | 2,085,489 |
| Richard Byrd | PSU | 2024-11-26 | 2,211 | 4,422 | — | 8,844 | 947,988 |
| Thomas Polen | RSU | 2024-11-26 | — | — | 60,891 | — | 3,311,861 |
| Michael Feld | RSU | 2024-11-26 | — | — | 10,004 | — | 544,118 |
| Michael Garrison | RSU | 2024-11-26 | — | — | 10,004 | — | 544,118 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Feld | $1,095,592 | $1,090,122 | $0 | 49.9% |
| Michael Garrison | 1,095,592 | 1,090,122 | 0 | 49.9% |
| Richard Byrd | 952,681 | 947,988 | 0 | 49.9% |
| Christopher DelOrefice | 2,095,909 | 2,085,489 | 0 | 49.9% |
| Thomas Polen | 6,668,440 | 6,635,275 | 0 | 49.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Byrd | SAR | 8,699 | 224.25 | — |
| Michael Garrison | RSU | 7,371 | — | 1,379,630 |
| Christopher DelOrefice | RSU | 14,137 | — | 2,646,022 |
| Michael Garrison | SAR | 4,734 | 238.06 | — |
| Thomas Polen | RSU | 49,539 | — | 9,272,215 |
| Christopher DelOrefice | PSU | 36,632 | — | 6,856,411 |
| Michael Feld | PSU | 10,170 | — | 1,903,519 |
| Thomas Polen | SAR | 34,984 | 238.06 | — |
| Richard Byrd | SAR | 3,705 | 238.06 | — |
| Thomas Polen | SAR | 60,891 | 224.25 | — |
| Christopher DelOrefice | SAR | 19,138 | 224.25 | — |
| Thomas Polen | SAR | 19,222 | 241.1 | — |
| Christopher DelOrefice | SAR | 9,330 | 238.06 | — |
| Christopher DelOrefice | SAR | 4,738 | 241.1 | — |
| Richard Byrd | SAR | 1,992 | 241.1 | — |
| Michael Garrison | SAR | 1,992 | 241.1 | — |
| Thomas Polen | PSU | 120,938 | — | 22,635,965 |
| Michael Garrison | PSU | 19,832 | — | 3,711,955 |
| Richard Byrd | PSU | 16,358 | — | 3,061,727 |
| Richard Byrd | RSU | 5,985 | — | 1,120,212 |
| Thomas Polen | SAR | 47,502 | 238.89 | — |
| Michael Feld | RSU | 6,976 | — | 1,305,698 |
| Christopher DelOrefice | SAR | 13,819 | 238.89 | — |
| Richard Byrd | SAR | 6,046 | 238.89 | — |
| Michael Garrison | SAR | 7,773 | 238.89 | — |
| Michael Feld | SAR | 10,004 | 224.25 | — |
| Michael Garrison | SAR | 10,004 | 224.25 | — |
Our goal is to provide an executive compensation program that best serves the long-term interests of our shareholders. We believe that attracting and retaining superior talent and rewarding performance is key to delivering long-term shareholder returns, and that a competitive compensation program is critical to that end.
| CEO STI target (% of salary) | 156% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-01-27 | 219,718,308 | 20,659,474 | 1,176,517 | 91.41% | Passed |
| 2025 | 2025-01-28 | 208,413,830 | 25,696,707 | 622,784 | 89.02% | Passed |
| 2024 | 2024-01-23 | 220,789,127 | 17,666,312 | 1,650,510 | 92.59% | Passed |
| 2023 | 2023-01-24 | 218,048,059 | 16,612,567 | 773,923 | 92.92% | Passed |
| 2022 | 2022-01-25 | 182,848,043 | 48,903,644 | 573,457 | 78.9% | Passed |
| 2021 | 2021-01-26 | 155,094,897 | 76,265,280 | 1,138,722 | 67.04% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-01-27 | 91.41%a |
| 2025 | 2025-01-28 | 89.02%b |
| 2024 | 2024-01-23 | 92.59%c |
a. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
b. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
c. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 374 : 1 |
|---|---|
| CEO total compensation | $17,129,140 |
| Median employee compensation | $45,831 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bertram L. ScottIndependent · Lead Independent Director · Compensation and Human Capital · Quality and Regulatory | $160,000 | $215,172 | $0 | $0 | $0 | $375,172 |
| Christopher JonesIndependent · Audit · Corporate Governance and Nominating (Chair) | 145,000 | 215,172 | 0 | 0 | 5,000 | 365,172 |
| R. Andrew EckertIndependent · Audit · Compensation and Human Capital (Chair) | 145,000 | 215,172 | 0 | 0 | 5,000 | 365,172 |
| Jeffrey W. HendersonIndependent · Audit (Chair) · Compensation and Human Capital | 145,000 | 215,172 | 0 | 0 | 0 | 360,172 |
| Catherine M. BurzikIndependent · Corporate Governance and Nominating · Quality and Regulatory (Chair) · Not standing for re-election | 145,000 | 215,172 | 0 | 0 | 0 | 360,172 |
| Carrie L. ByingtonIndependent · Audit · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 10,000 | 345,172 |
| Claire M. FraserIndependent · Compensation and Human Capital · Corporate Governance and Nominating | 120,000 | 215,172 | 0 | 0 | 9,500 | 344,672 |
| Joanne WaldstreicherIndependent · Corporate Governance and Nominating · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 1,000 | 336,172 |
| William M. BrownIndependent · Compensation and Human Capital · Corporate Governance and Nominating | 120,000 | 215,172 | 0 | 0 | 0 | 335,172 |
| Timothy M. RingIndependent · Audit · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 0 | 335,172 |
| Gregory J. HayesIndependent · Audit · Compensation and Human Capital · Newly elected | 42,125 | 181,329 | 0 | 0 | 0 | 223,454 |
| Jacqueline WrightIndependent · Audit · Compensation and Human Capital · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Thomas E. PolenEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Robert L. HuffinesIndependent · Audit · Corporate Governance and Nominating · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $120,000 |
|---|---|
| Annual equity retainer | $215,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 5x annual cash retainer ($600,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,382,125 |
| Equity awards (grant-date value) | $2,333,049 |
| All other compensation | $30,500 |
| Total cost of the board | $3,745,674 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies BECTON DICKINSON & CO names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including BECTON DICKINSON & CO.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 4 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 5 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 6 | Medtronic plc | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 7 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 8 | GE Healthcare Technologies, Inc. | 2025 | Peter Arduini | 1,324,983 | 11,249,533 | 3,624,970 | 2,081,084 | 18,562,794 |
| 9 | BECTON DICKINSON & CO | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 10 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 11 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| BECTON DICKINSON & CO | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Baxter International Inc. | not disclosed | not disclosed | No | Aon Consulting, Inc. (Aon) |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | Yes — Relative TSR | FW Cook |
| GE Healthcare Technologies, Inc. | 101% | PSU 50 · Option 25 · RSU 25 | No | Semler Brossy |
| Medtronic plc | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Thomas Polen | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 2 | Section 01, Christopher DelOrefice | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 5,877,164. Filing ↗machine: r5 · c27 · span 1183378–1183387 |
| 3 | Section 01, Michael Feld | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 4,096,356. Filing ↗machine: r10 · c27 · span 1200214–1200223 |
| 4 | Section 01, Michael Garrison | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 3,649,040. Filing ↗machine: r11 · c27 · span 1204119–1204128 |
| 5 | Section 01, Richard Byrd | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 3,399,056. Filing ↗machine: r8 · c27 · span 1193413–1193422 |
| 6 | Section 03, Michael Feld PSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Michael Garrison PSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Richard Byrd RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1292120–1292127 |
| 9 | Section 03, Christopher DelOrefice RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1283483–1283492 |
| 10 | Section 03, Thomas Polen PSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1270861–1270870 |
| 11 | Section 03, Michael Feld RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1298659–1298666 |
| 12 | Section 03, Richard Byrd RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1289996–1290003 |
| 13 | Section 03, Michael Garrison RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1307334–1307341 |
| 14 | Section 03, Thomas Polen RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1272703–1272712 |
| 15 | Section 03, Christopher DelOrefice RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1281356–1281365 |
| 16 | Section 03, Christopher DelOrefice PSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 17 | Section 03, Richard Byrd PSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 18 | Section 03, Thomas Polen RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1274830–1274839 |
| 19 | Section 03, Michael Feld RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1300784–1300791 |
| 20 | Section 03, Michael Garrison RSU | DEF 14A | 1900-01-01 | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1309939–1309946 |
| 21 | Section 07, pay ratio | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “CEO Pay Ratio”. As printed: 374 : 1. Filing ↗machine: span 1525421–1525429 |
| 22 | Section 08, Bertram L. Scott | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 375,172. Filing ↗machine: t109 · r12 · c7 · span 765078–765322 |
| 23 | Section 08, Christopher Jones | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 365,172. Filing ↗machine: t109 · r10 · c7 · span 761701–761945 |
| 24 | Section 08, R. Andrew Eckert | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 365,172. Filing ↗machine: t109 · r5 · c7 · span 752360–752604 |
| 25 | Section 08, Jeffrey W. Henderson | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 360,172. Filing ↗machine: t109 · r8 · c7 · span 757950–758219 |
| 26 | Section 08, Catherine M. Burzik | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 360,172. Filing ↗machine: t109 · r3 · c7 · span 748904–749148 |
| 27 | Section 08, Carrie L. Byington | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 345,172. Filing ↗machine: t109 · r4 · c7 · span 750642–750886 |
| 28 | Section 08, Claire M. Fraser | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 344,672. Filing ↗machine: t109 · r6 · c7 · span 754135–754404 |
| 29 | Section 08, Joanne Waldstreicher | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 336,172. Filing ↗machine: t109 · r13 · c7 · span 766806–767075 |
| 30 | Section 08, William M. Brown | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 335,172. Filing ↗machine: t109 · r2 · c7 · span 747007–747249 |
| 31 | Section 08, Timothy M. Ring | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 335,172. Filing ↗machine: t109 · r11 · c7 · span 763414–763658 |
| 32 | Section 08, Gregory J. Hayes | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 223,454. Filing ↗machine: t109 · r7 · c7 · span 756132–756401 |
| 33 | Section 08, Jacqueline Wright | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t109 · r14 · c7 · span 769240–769241 |
| 34 | Section 08, Thomas E. Polen | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 08, Robert L. Huffines | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t109 · r9 · c7 · span 760129–760130 |
| 36 | Section 02, Michael Feld 2025-12-26 | Form 4 | 2025-12-29 | 0001628280-25-058843 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, David Shan 2026-01-03 | Form 4 | 2026-01-06 | 0001963048-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Pamela L. Spikner 2026-01-21 | Form 4 | 2026-01-23 | 0002012329-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michael Feld 2026-01-26 | Form 4 | 2026-01-28 | 0001628280-26-003734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Bertram L. Scott 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Robert L. Huffines 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, R. Andrew Eckert 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Joanne Waldstreicher 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-003999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Gregory J. Hayes 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Carrie L. Byington 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jeffrey W. Henderson 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Jacqueline Wright 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-003997 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Timothy M. Ring 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Christopher Jones 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, William M. Brown 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Carrie L. Byington 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005695 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Christopher Jones 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005690 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Robert L. Huffines 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005700 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, BECTON DICKINSON & CO 2026-02-09 | Form 4 | 2026-02-11 | 0001193125-26-046606 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Bertram L. Scott 2026-02-18 | Form 4 | 2026-02-18 | 0001628280-26-009242 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michael Feld 2026-02-26 | Form 4 | 2026-02-27 | 0001628280-26-012955 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Pamela L. Spikner 2026-03-02 | Form 4 | 2026-03-04 | 0001628280-26-014438 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Vitor Roque 2026-03-02 | Form 4 | 2026-03-04 | 0001628280-26-014440 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Lanesha Minnix 2026-03-16 | Form 4 | 2026-03-17 | 0001628280-26-018607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Michael Feld 2026-03-26 | Form 4 | 2026-03-27 | 0001628280-26-021644 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Shana Carol Neal 2026-04-06 | Form 4 | 2026-04-06 | 0001628280-26-023944 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michael Feld 2026-04-27 | Form 4 | 2026-04-28 | 0001628280-26-027731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Vitor Roque 2026-05-07 | Form 4 | 2026-05-08 | 0001628280-26-032999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Carrie L. Byington 2026-05-08 | Form 4 | 2026-05-08 | 0001628280-26-033022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Robert L. Huffines 2026-05-08 | Form 4 | 2026-05-08 | 0001628280-26-033027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Michael Feld 2026-05-26 | Form 4 | 2026-05-27 | 0001628280-26-038382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Peter Menziuso 2026-06-01 | Form 4 | 2026-06-02 | 0001628280-26-039738 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Michael Garrison 2026-06-10 | Form 4 | 2026-06-11 | 0001628280-26-042571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Michael Garrison 2026-06-24 | Form 4 | 2026-06-25 | 0001628280-26-045374 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Michael Feld 2026-06-26 | Form 4 | 2026-06-26 | 0001628280-26-045864 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Bilal Muhsin 2026-07-01 | Form 4 | 2026-07-06 | 0001628280-26-047193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Bilal Muhsin 2026-07-02 | Form 4 | 2026-07-06 | 0001628280-26-047193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Michael Feld 2026-07-27 | Form 4 | 2026-07-28 | 0001628280-26-049989 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Carrie L. Byington 2026-08-06 | Form 4 | 2026-08-06 | 0001628280-26-054418 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Robert L. Huffines 2026-08-06 | Form 4 | 2026-08-06 | 0001628280-26-054422 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Roland Goette 2026-08-11 | Form 4 | 2026-08-12 | 0001628280-26-056366 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Thomas E. Polen Jr 2026-08-13 | Form 4 | 2026-08-14 | 0001628280-26-057166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Thomas E. Polen Jr 2026-08-13 | Form 4 | 2026-08-14 | 0001628280-26-057166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Thomas E. Polen Jr 2026-08-13 | Form 4 | 2026-08-14 | 0001628280-26-057166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Thomas E. Polen Jr 2026-08-13 | Form 4 | 2026-08-14 | 0001628280-26-057166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Michael Feld 2026-08-20 | Form 4 | 2026-08-24 | 0001628280-26-058647 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Michael Feld 2026-08-26 | Form 4 | 2026-08-27 | 0001628280-26-059269 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Vitor Roque 2026-09-02 | Form 4 | 2026-09-03 | 0001628280-26-060580 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Michael Feld 2026-09-28 | Form 4 | 2026-09-29 | 0001628280-26-063882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 06, 2026 vote | Form 8-K | 2026-01-30 | 0001628280-26-004393 | Item 5.07 · say-on-pay result. As reported: 91.41% (votes for as printed: 219,718,308). Filing ↗ |
| 95 | Section 06, 2025 vote | Form 8-K | 2025-01-31 | 0000010795-25-000011 | Item 5.07 · say-on-pay result. As reported: 89.02% (votes for as printed: 208,413,830). Filing ↗ |
| 96 | Section 06, 2024 vote | Form 8-K | 2024-01-26 | 0000010795-24-000006 | Item 5.07 · say-on-pay result. As reported: 92.59% (votes for as printed: 220,789,127). Filing ↗ |
| 97 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 98 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 99 | Section 09b board cost (computed) | Computed | — | — | Cash 1,382,125 + equity 2,333,049 + all other 30,500 = 3,745,674, summed across the director compensation table rows.machine: formula: Σ = 3,745,674 |
| 100 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 101 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 102 | Abbott Laboratories, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001308179-26-000064 | CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498 |
| 103 | Danaher Corporation, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000313616-26-000101 | CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190 |
| 104 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 105 | Medtronic plc, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 106 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 107 | GE Healthcare Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-03-19 | 0001932393-26-000021 | CEO total compensation as printed in GE Healthcare Technologies, Inc.'s own proxy. As printed: 18,562,794. Filing ↗machine: r3 · c39 · span 924977–924987 |
| 108 | BECTON DICKINSON & CO (subject), Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in BECTON DICKINSON & CO's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 109 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 110 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 111 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc. names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 112 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include BECTON DICKINSON & CO. Filing ↗ |
| 113 | Section 10a, GE Healthcare Technologies, Inc. reciprocity | DEF 14A | — | 0001932393-26-000021 | GE Healthcare Technologies, Inc. names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 114 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc. names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 115 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 116 | Section 10a, Danaher Corporation reciprocity | DEF 14A | — | 0000313616-26-000101 | Danaher Corporation names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 117 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation names BECTON DICKINSON & CO in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the BECTON DICKINSON & CO Executive Compensation Report
$1,500